Faecalibacterium prausnitzii EXL01 (Exeliom)

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameFaecalibacterium prausnitzii EXL01 (Exeliom)
Drug Alias NameEXL-01EXL01
ClassificationNatural product/Extract > Microbial extract
Mechanisms of ActionInterleukin-10 stimulantsGastrointestinal microbiome modulatorsBacteria replacements
TargetsInterleukin-10
Therapy Area/IndicationsCrohn DiseaseCarcinoma, Non-Small-Cell LungStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesExeliom Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesExeliom BiosciencesCenter Eugene MarquisGercor - Multidisciplinary Oncology Cooperative Group +[4] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsCarcinoma, Renal Cell +[6] 
Inactive IndicationsCrohn Disease

Other Information

ATC CodeN/A
Related LinksN/A